With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...
United Therapeutics Corporation Strong Buy: phase 3 Tyvaso wins in IPF boost FVC, support summer sNDA and Priority Review ...
Medical Watch Digest for March 31 Potential treatment could clear scar tissue from lungs Scientists think they have ...
United Therapeutics (NASDAQ:UTHR) surged more than 12% in pre-market trading on March 30 after positive TETON-1 trial data ...
Pulmonary fibrosis is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition, ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 30, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the ...
Avalyn, a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the initiation of the AURA ...
Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, ...
Researchers at the Institute of Industrial Science, the University of Tokyo, have developed a system that allows human lung ...
A new study from the University of Bergen shows that genes responsible for antibiotic resistance are present not only in ...
Study finds higher antimicrobial resistance genes in lung disease patients, with antibiotic use linked to increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results